Complement disorders and hemolytic uremic syndrome

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose of review

Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS.

Recent findings

In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins.

Summary

Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver–kidney transplantation offer promise for improved prognosis.

Related Topics

    loading  Loading Related Articles